Spasenija Savic
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
Savic S, Soltermann A, Zweifel R, Zettl A, von Gunten M, Singer G, Rössle M, Jasarevic Z, Letovanec I, McKee T, Komminoth P, Jochum W, Fleischmann A, Diebold J, Cathomas G, Eppenberger-Castori S, Berezowska S, Bubendorf L. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study. Virchows Arch 2019; 475:67-76.
May 24, 2019PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study
May 24, 2019Virchows Arch 2019; 475:67-76
Savic Spasenija, Soltermann Alex, Zweifel Roland, Zettl Andreas, von Gunten Michael, Singer Gad, Rössle Matthias, Jasarevic Zerina, Letovanec Igor, McKee Thomas, Komminoth Paul, Jochum Wolfram, Fleischmann Achim, Diebold Joachim, Cathomas Gieri, Eppenberger-Castori Serenella, Berezowska Sabina, Bubendorf Lukas
A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poechtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. Clin Cancer Res 2019; 25:3026-3034.
Feb 14, 2019A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer
Feb 14, 2019Clin Cancer Res 2019; 25:3026-3034
Trefny Marcel P, Savic Spasenija, Jermann Philip, Alborelli Ilaria, Schaub Stefan, Stenner Frank, Früh Martin, Trajanoski Zlatko, Flatz Lukas, Mertz Kirsten D, Zippelius Alfred, Geier Florian, Thommen Daniela S, Rothschild Sacha I, Uhlenbrock Franziska, Rieder Dietmar, Kasenda Benjamin, Stanczak Michal A, Berner Fiamma, Kashyap Abhishek S, Kaiser Monika, Herzig Petra, Poechtrager Severin, Läubli Heinz
Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Metaxas Y, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, O'Byrne K, Petrausch U, Wolleb S, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak A, Gautschi O, Bartnick T, Hughes B, Bouchaab H, Rothschild S, Pavlakis N, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. J Thorac Oncol 2018
Aug 21, 2018Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
Aug 21, 2018J Thorac Oncol 2018
Metaxas Yannis, Froesch Patrizia, Löffler-Baumann Melanie, Pratsch-Peter Susanne, Russell Prudence, Mingrone Walter, Savic Spasenija, Thapa Bibhusal, Früh Martin, Pless Miklos, von Moos Roger, Mauti Laetitia, O'Byrne Kenneth, Petrausch Ulf, Wolleb Sybille, Rivalland Gareth, Klingbiel Dirk, Kao Steven, Schmid Sabine, Nowak Anna K, Gautschi Oliver, Bartnick Tammo, Hughes Brett G, Bouchaab Hasna, Rothschild Sacha, Pavlakis Nick, John Thomas
Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
Savic S, Kerr K, Bisig B, Tornillo L, Grieshaber S, Baschiera B, Jochum W, Zimmermann A, Diebold J, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015; 89:104-9.
May 21, 2015Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended
May 21, 2015Lung Cancer 2015; 89:104-9
Savic Spasenija, Kerr Keith, Bisig Bettina, Tornillo Luigi, Grieshaber Susanne, Baschiera Betty, Jochum Wolfram, Zimmermann Anne-Katrin, Diebold Joachim, Bubendorf Lukas
Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Gautschi O, Savic S, Jaggi R, Leibundgut E, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A, Bubendorf L, Feilchenfeldt J, Rauch D, Mach N, Rothschild S, Li Q, Stahel R, Zippelius A, Cathomas R, Früh M, Betticher D, Peters S, Swiss Group for Clinical Cancer Research. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.
Mar 5, 2015Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09
Mar 5, 2015Clin Lung Cancer 2015; 16:358-65
Gautschi Oliver, Savic Spasenija, Jaggi Rolf, Leibundgut Elisabeth Oppliger, Largiadèr Carlo, Brutsche Martin, Pilop Christiane, Stalder Lukas, Pless Miklos, Ochsenbein Adrian F, Bubendorf Lukas, Feilchenfeldt Jonas, Rauch Daniel, Mach Nicholas, Rothschild Sacha I, Li Qiyu, Stahel Rolf A, Zippelius Alfred, Cathomas Richard, Früh Martin, Betticher Daniel C, Peters Solange, Swiss Group for Clinical Cancer Research
Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg J, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter J, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2013; 19:973-80.
Apr 2, 2013Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
Apr 2, 2013Biol Blood Marrow Transplant 2013; 19:973-80
Holbro Andreas, Lehmann Thomas, Girsberger Sabine, Stern Martin, Gambazzi Franco, Lardinois Didier, Heim Dominik, Passweg Jakob R, Tichelli André, Bubendorf Lukas, Savic Spasenija, Hostettler Katrin, Grendelmeier Peter, Halter Joerg P, Tamm Michael
Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Tapia C, Glatz K, Obermann E, Grilli B, Barascud A, Herzog M, Schönegg R, Savic S, Bubendorf L. Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology. Cancer Cytopathol 2011; 119:404-10.
Jul 5, 2011Evaluation of chromosomal aberrations in patients with benign conditions and reactive changes in urinary cytology
Jul 5, 2011Cancer Cytopathol 2011; 119:404-10
Tapia Coya, Glatz Kathrina, Obermann Ellen C, Grilli Bruno, Barascud Audrey, Herzog Michelle, Schönegg René, Savic Spasenija, Bubendorf Lukas
Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology
Savic S, Herman J, Clark D, Zlobec I, Schönegg R, Spieler P, Loosli H, Bode B, Herzog M, Barascud A, Grilli B, Franco N, Bubendorf L. Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest 2010; 138:137-44.
Feb 5, 2010Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology
Feb 5, 2010Chest 2010; 138:137-44
Savic Spasenija, Herman James G, Clark Douglas P, Zlobec Inti, Schönegg René, Spieler Peter, Loosli Heinz, Bode Beata, Herzog Michelle, Barascud Audrey de Vito, Grilli Bruno, Franco Noreli, Bubendorf Lukas
Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. American journal of respiratory and critical care medicine 2010; 181:181-8.
Jan 15, 2010Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
Jan 15, 2010American journal of respiratory and critical care medicine 2010; 181:181-8
Baty Florent, Tamm Michael, Kehren Jeanne, Buess Martin, Budach Wolfgang, Marrer Estelle, Savic Spasenija, Bubendorf Lukas, Pless Miklos, Schumacher Martin, Kaiser Sergio, Facompre Michael, Brutsche Martin
Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens
Zlobec I, Raineri I, Schneider S, Schönegg R, Grilli B, Herzog M, Savic S, Bubendorf L. Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens. Lung cancer (Amsterdam, Netherlands) 2009
Jul 17, 2009Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimens
Jul 17, 2009Lung cancer (Amsterdam, Netherlands) 2009
Zlobec Inti, Raineri Ines, Schneider Sandra, Schönegg René, Grilli Bruno, Herzog Michelle, Savic Spasenija, Bubendorf Lukas
The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
Savic S, Casella R, Zellweger T, Forster T, Sulser T, Gasser T, Schönegg R, Spieler P, Dalquen P, Eichenberger T, Mattarelli G, Lehmann K, Schmauss M, Engeler D, Thalmann G, Zlobec I, Bubendorf L. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy. International journal of cancer. Journal international du cancer 2009; 124:2899-904.
Jun 15, 2009The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy
Jun 15, 2009International journal of cancer. Journal international du cancer 2009; 124:2899-904
Savic Spasenija, Casella Roberto, Zellweger Tobias, Forster Thomas, Sulser Tullio, Gasser Thomas C, Schönegg René, Spieler Peter, Dalquen Peter, Eichenberger Tobias, Mattarelli Gianfranco, Lehmann Kurt, Schmauss Martina, Engeler Daniel, Thalmann George N, Zlobec Inti, Bubendorf Lukas
HER2 gene status in primary breast cancers and matched distant metastases
Tapia C, Feichter G, Terracciano L, Cathomas G, Zlobec I, Barascud A, Herzog M, Grilli B, Novotny H, Schönegg R, Wagner U, Savic S, Bubendorf L. HER2 gene status in primary breast cancers and matched distant metastases. Breast cancer research : BCR 2007; 9:R31.
Jan 1, 2007HER2 gene status in primary breast cancers and matched distant metastases
Jan 1, 2007Breast cancer research : BCR 2007; 9:R31
Tapia Coya, Feichter Georg, Terracciano Luigi, Cathomas Gieri, Zlobec Inti, Barascud Audrey Devito, Herzog Michelle, Grilli Bruno, Novotny Hedvika, Schönegg René, Wagner Urs, Savic Spasenija, Bubendorf Lukas